Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly

Drugs and Aging

Volumn 16, Issue 2, 2000, Pages 123-138

  VanDenBerg, Chad M ^a   Kazmi, Yusuf ^a   Jann, Michael W ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0034091808     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200016020-00004     Document Type: Review

References (96)

1. 1. Eggert A, Crismon ML, Ereshefsky L. Alzheimer's disease. In: Dipiro J, Talbet RL, Yee GC, et al., editors. Pharmacotherapy. 3rd ed. New York: Elsiever, 1997: 1325-44
2. 2. Brawn LA, Castleden CM. Adverse drug reactions: an overview of special considerations in the management of the elderly patient. Drug Saf 1990; 5 (6): 421 -35
3. 3. Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clin Pharmacokinet 1998; 35 (1): 49-64
4. 4. Catterson ML, Preskorn SH, Martin RL. Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. Psychiatr Clin North Am 1997; 20 (1): 205-18
5. 5. Crismon ML. Tacrine: the first drug approved for Alzheimer's disease. Ann Pharmacother 1994; 28: 744-51
6. 6. Rogers SL, Doody RS, Mohs RC, the Donepezil Study Group, et al. Donepezil improves the cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 58: 1021-31
7. 7. Rainer M. Galanthamine in Alzheimer's disease: a new alternative 10 tacrine? CNS Drugs 1997; 7 (2): 89-97
8. 8. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998; 20 (4): 634-47
9. 9. Unni LK, Hutt V, Imbimbo BP, et al. Kinetics of cholinesterase inhibition by eptastigmine in man. Eur J Clin Pharmacol 1991; 41: 83-4
10. 10. Jann MW. Preclinical pharmacology of metrifonate. Pharmacotherapy 1998; 18 (2 Pt 2); 55-67S
11. 11. Rowland M, Tozer TN. Elimination. In: Clinical pharmacokinetics: concepts and applications. 2nd ed. Malvern (PA): Lea & Febiger, 1989: 148-76
12. 12. Williams L, Lowenthal DT. Drug therapy in the elderly. South Med J 1992; 85 (2): 127-31
13. 13. Chutka DS, Evans JM, Fleming KC, et al. Drug prescribing for elderly patients. Mayo Clin Proc 1995; 70: 685-93
14. 14. O'Connell MB, Dwindell AM, Bannick-Mohrland SD. Predictive performance of equations to estimate creatinine clearance in hospitalized elderly patients. Ann Pharmacother 1992; 26: 627-35
15. 15. Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf 1998; 19 (6): 465-80
16. 16. Auteri A, Mosca A, Lattuada N, et al. Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. Eur J Clin Pharmacol 1993; 45 (4): 373-6
17. 17. Ohnishi A, Mihara M, Kamakura H, et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol 1993; 33: 1086-91
18. 18. Schran HF, Habucky K, Mancione LC, et al. The effects of renal and hepatic impairment on the disposition of the acetylcholinesterasc (AChE) inhibitor SDX ENA 713 [abstract]. Pharmacol Res 1996; 13: S428
19. 19. Tiseo PJ, Varga R, Perdomo CA, et al. An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function. Br J Clin Pharmacol 1998; 46 Suppl. 1: 51-5
20. 20. Tiseo PJ, Foley K, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients wiih moderately to severely impaired renal function. Br J Clin Pharmacol 1998; 46 Suppl. 1: 56-60
21. 21. Parke-Davis. Cognex (tacrine hydrochloride): prescribing information. Morris Plains (NJ): Parke-Davis, 1993
22. 22. Masters CL, Beyreuther K. Alzheimer's disease. BMJ 1998; 316: 446-8
23. 23. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 1993; 16: 460-5
24. 24. Iqbal K, Alonso AC, Gong CX, et al. Alzheimer neurofibrillary degeneration: a feasible and key target for therapeutics. In: Becker R, Giacobini E, editors. Alzheimer disease: from molecular biology to therapy. Boston (MA): Birkhauser, 1996: 31-6
25. 25. Vogel G. Tau protein mutations confirmed as neuron killers. Science 1998; 280: 1524-5
26. 26. Cordell B. β-Amyloid formation as a potential therapeutic target for Alzheimer's disease. Annu Rev Pharmacol Toxicol 1994; 34: 69-89
27. 27. Selkoe D. Amyloid protein and Alzheimer's disease. Sci Am 1991; 265: 68-78
28. 28. Oltersdorf T, Fritz LC, Schen DB, et al. The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is the protease nexin-II. Nature 1989; 341: 144-7
29. 29. Smith RP, Higuchi DA, Broze GJ. Platelet coagulation factor Xia-inhibitor, a form of Alzheimer amyloid precursor protein. Science 1990; 248: 1126-8
30. 30. Qiu WQ, Ferreira A, Miller C, et al. Cell-surface β-amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner. J Neurosci 1995; 15: 217-67
31. 31. Saitoh T, Sundsmo M, Roch JM, et al. Secreted form of amyloid α protein precursor is involved in the growth regulation of fibroblasts. Cell 1989; 58: 615-22
32. 32. Mattson MP, Cheng B, Culwell AR, et al. Evidence for excitoprotective and intraveuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 1993; 10: 243-54
33. 33. Geerts H, Nuydens R, de Jong M, et al. A new focus on cytoskeletal therapy in Alzheimer's disease. In: Becker R, Giacobini E, editors. Alzheimer disease: from molecular biology to therapy. Boston (MA): Birkhauser, 1996: 61-5
34. 34. Chevallier N, Marambaud P, Vincent JP, et al. Novel cathepsin D inhibitors prevent the β-secretase-derived intracellular formation of a 12 kDa potentially amyloidogenic product in human cells. In: Becker R, Giacobini E, editors. Alzheimer disease: from molecular biology to therapy. Boston (MA): Birkhauser, 1996: 67-73
35. 35. Cacabelos R, Hofman A, Mullan M, et al. Alzheimer's disease: scientific progress for future trends. DN&P 1993; 6: 242-4
36. 36. Cacabelos R, Nordberg A, Caamaño J, et al. Therapeutic strategies in Alzheimer's disease. Ann Psychiatry 1995; 4: 221-79
37. 37. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994; 151: 1105-13
38. 38. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996; 47: 876-83
39. 39. Young AB, Penney JB. Neurotransmitter receptors in Alzheimer's disease. In: Terry RD, Katzman R, Bick KL, editors. Alzheimer's disease. New York (NY): Raven Press, 1994: 293-303
40. 40. Steele CD, Steinberg M, Milles G, et al. Recognition and management of early Alzheimer's disease. J Clin Outcomes Manage 1999; 6 (3): 52-68
41. 41. Parnetti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease. Drugs 1997; 53 (3): 752-68
42. 42. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 2523-9
43. 43. Knapp MJ, Knopman DS, Soloman PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-91
44. 44. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled, trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45
45. 45. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65
46. 46. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-40
47. 47. Cummings JL, Cyrus PA, Bierber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease: the Metrifonate Study Group. Neurology 1998; 50: 1214-21
48. 48. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998; 50: 1222-30
49. 49. Thal LJ, Schwartz G, Sano M, et al. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology 1996; 47: 1389-95
50. 50. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. JAMA 1997; 278 (16): 1363-71
51. 51. Food, Drug and Cosmetic Reports. FDA guidance on Alzheimer's drug clinical utility assessments. FDC Rep 1992: 13-5
52. 52. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327: 1253-9
53. 53. Kluger A, Ferris H. Scales for the assessment of Alzheimer's disease. Psychiatr Clin North Am 1991; 14 (2): 309-26
54. 54. Morgan CD, Baade LE. Neuropsychological testing and assessment scales for dementia of the Alzheimer's type. Psychiatr Clin North Am 1997; 20 (1): 25-43
55. 55. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64
56. 56. Dal-Bianco P, Maly J, Wober C, et al. Galanthamine treatment in Alzheimer's disease. J Neural Transm 1991; Suppl. 33: 59-63
57. 57. Wilcock G, Wilkinson D. Galanthamine hydrobromide: interim results of a group comparative, placebo-controlled study of the efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer's type. Neurobiol Aging 1996; 17 Suppl. 4: S144
58. 58. Knopman DS, Knapp MJ, Gracon SI, et al. The clinician interview based impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994; 44: 2315-21
59. 59. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol 1996; 9: 1-6
60. 60. Cummings JL. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology 1997; 48 Suppl. 6: S10-16
61. 61. Riter RN, Fries BE. Predictors of the placement of cognitively impaired residents on special care units. Gerontologist 1992; 32: 184-90
62. 62. DeJong R, Osterlund OW, Roy GW. Measurement of quality of life changes in patients with Alzheimer's disease. Clin Ther 1989; 11 (4): 545-54
63. 63. Cutler NR, Sramek JJ. The bridging study: optimizing the dose for phase II/III. In: Becker R, Giacobini E, et al. Alzheimer disease: from molecular biology to therapy. Boston (MA): Birkhauser, 1996: 387-91
64. 64. Cutler NR, Jhee SS, Cyrus P, et al. Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study. Life Sci 1998; 62 (16): 1433-41
65. 65. Mant T, Troetel WM, Imbimbo BP. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers. J Clin Pharmacol 1998; 38: 610-7
66. 66. Ford JM, Truman CA, Wilcock GK, et al. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clin Pharmacol Ther 1993; 53: 691-5
67. 67. Rogers SL, Cooper NM, Sukavaty R, et al. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Pharmacol 1998; 46 Suppl. 1: 7-12
68. 68. Cutler NR, Anand R, Hartman RD, et al. Antiemetic therapy for Alzheimer's patients receiving the cholinesterase inhibitor SDZ ENA 713 [abstract]. Clin Pharmacol Ther 1998; 63 (2): 188
69. 69. Sarin S, Gill KD. Biochemical and behavioral deficits in adult rat following chronic dichlorvos exposure. Pharmacol Biochem Behav 1998; 59 (4): 1081-6
70. 70. Glynn P, Holton JL, Nolan CC, et al. Neuropathy target esterase: immunolocalization to neuronal cell bodies and axons. Neuroscience 1998; 83 (1): 295-302
71. 71. Ehrich M, Correll L, Veronesi B. Acetylcholinesterase and neuropathy target esterase inhibitions in neuroblastoma cells to distinguish organophosphorus compounds causing acute and delayed neurotoxicity. Fundam Appl Toxicol 1997; 38 (1): 55-63
72. 72. Fournier L, Musard D, Lecorsier A. Lymphocyte esterases and hydroxylases in neurotoxicology. Vet Hum Toxicol 1996; 38 (3): 190-5
73. 73. Sterri SH, Lyngaas S, Fonnum F. Toxicity of soman after repetitive injection of sublethal doses in guinea-pig and mouse. Acta Pharmacol Toxicol (Copenh) 1981; 49: 8-13
74. 74. Williams FM, Charlton C, de Blaquiere GE, et al. The effects of multiple low doses of organophosphates on target enzymes in brain and diaphragm in the mouse. Hum Exp Toxicol 1997; 16: 67-71
75. 75. Mennear JH. Dichlorvos carcinogenicity: an assessment of the weight of experimental evidence. Regul Toxicol Pharmacol 1994; 20 (3 Pt 1): 354-61
76. 76. Anonymous. Bayer suspends metrifonate trials. Scrip 1998 Sep 30; 2374: 19
77. 77. Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrinc administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-8
78. 78. Chan PC, Huff J, Haseman JK, et al. Carcinogenesis studies of dichlorvos in Fischer rats and B6C3F1 mice. Jpn J Cancer Res 1991; 82 (2): 157-64
79. 79. Blair D, Dix KM, Hunt PF, et al. Dichlorvos: a two-year inhalation carcinogenesis study in rats. Arch Toxicol 1976: 281-94
80. 80. Zeiger E, Erexson G, Mortelmans K, et al. Genetic toxicity studies of 1,2,3,4-tetrahydro-9-acridinamine (tacrine). Mutat Res 1997; 393 (3): 189-97
81. 81. Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998; 12 (6): 485-94
82. 82. Crismon ML. Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease. Pharmacothcrapy 1998; 18 (2 Pt 2): 47-54S
83. 83. Becquemont L, Ragueneau I, Le Bot MA, et al. Influence of the CYPIA2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997; 61: 619-27
84. 84. Becquemont L, Le Bot MA, Riche C, et al. Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. Pharmacogenetics 1998; 8: 101-8
85. 85. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84-112
86. 86. Welty D, Pool W, Woolf T, et al. The effect of smoking on the pharmacokinetics and metabolism of Cognex® in healthy volunteers [abstract], Pharmacol Res 1993; 10: S334
87. 87. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46 Suppl. 1: 30-4
88. 88. Tiseo PJ, Rogers SL, Perdomo CA, et al. The effect of cimetidine and ketoconazole on the pharmacokinetics of donepezil HCl [abstract]. Clin Pharmacol Ther 1998; 63 (2): 234
89. 89. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46 Suppl. 1: 25-9
90. 90. Eisai Inc. Aricept (donepezil hydrochloride): prescribing information. Teaneck (NJ): Eisai Inc., 1998
91. 91. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes. Br J Clin Pharmacol 1998; 46 Suppl. I: 40-4
92. 92. Tiseo PJ, Foley K, Friedhoff LT. Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers. Br J Clin Pharmacol 1998; 46 Suppl. 1: 35-9
93. 93. Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998; 46 Suppl. I: 45-50
94. 94. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact on delaying disease onset. Am J Public Health 1998; 88: 1337-42
95. 95. Lamb HM, Faulds D. Metrifonate. Drugs Aging 1997; 11 (6): 490-6
96. 96. Pettigrew LC, Bieber F, Lettieri J, et al. Pharmacokinetics, pharmacodynamics, and safely of metrifonate in patients with Alzheimer's disease. J Clin Pharmacol 1998; 38: 236-45